MedPath

The Clinical Utility of Glycated Albumin as an Index of Glycaemic Control in Type 1 Diabetic Pregnancy and its ability to predict Neonatal Outcome

Not Applicable
Completed
Conditions
Type 1 Diabetes
Pregnancy
Metabolic and Endocrine - Diabetes
Reproductive Health and Childbirth - Normal pregnancy
Registration Number
ACTRN12614001295639
Lead Sponsor
orthern Sydney Local Health District
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
30
Inclusion Criteria

Type 1 diabetes mellitus
- 11-18 weeks of gestation
- Aged > 18 years

Exclusion Criteria

- Severe renal impairment - > stage 3 chronic kidney disease
- Severe hepatic derangement - AST > 3 times upper limit of normal and/or ALT > 3 times upper limit of normal

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The correlation of measures of glycaemic control (as assessed by glycated albumin, HbA1c, fructosamine and 1,5-anhydroglucitol values) obtained throughout pregnancy with maternal and neonatal outcomes, particularly the incidence of macrosomia. Maternal and neonatal outcomes will be assessed by reviewing medical records and routine clinical data following delivery.<br>Maternal outcomes to be assessed include:<br>- Method of delivery (e.g. induction of labour, caesarean section)<br>- Perineal lacerations<br>- Postpartum haemorrhage<br>- Complications in labour<br>Neonatal outcomes to be assessed include:<br>- Birth weight<br>- Gestational age at birth<br>- Incidence of neonatal death<br>- Shoulder dystocia<br>- Bone fracture<br>- Nerve palsy<br>- Admission to neonatal intensive care unit (NICU)<br>- Hypoglycaemia<br>- Jaundice and/or jaundice requiring phototherapy<br>- Respiratory distress<br>[Post-pregnancy/delivery date]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath